# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-060084
Filing Date
2025-04-29
Accepted
2025-04-29 16:03:56
Documents
16
Period of Report
2025-05-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | nmra-20250429.htm iXBRL | DEF 14A | 1011917
2 | GRAPHIC | img236770955_0.jpg | GRAPHIC | 37470
3 | GRAPHIC | img236770955_1.jpg | GRAPHIC | 259594
4 | GRAPHIC | img236770955_2.jpg | GRAPHIC | 225512
| Complete submission text file | 0000950170-25-060084.txt |  | 2607507

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nmra-20250429.xsd | EX-101.SCH | 7930
19 | EXTRACTED XBRL INSTANCE DOCUMENT | nmra-20250429_htm.xml | XML | 5782

Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41802 | Film No.: 25887053
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)